Wednesday, July 8, 2026

Patent intelligence · US

US 10383943

Compositions and related methods for the treatment of cancer

granted A61KA61K31/555A61K45/06A61K47/542
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 13
Applicant portfolio 8,292
Patent details — US 10383943
Jurisdiction
US
Status
granted
Grant date
Aug 20, 2019
Expiration
Aug 15, 2039
Claims
16
CPC classes
A61K, A61K31/555, A61K45/06, A61K47/542
View on Google Patents ↗

Quick answer

US 10383943 (Compositions and related methods for the treatment of cancer) is held by SOUTH DAKOTA BOARD OF REGENTS. Status: granted. Granted Aug 20, 2019. Expires Aug 15, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
16
CPC classes
A61K, A61K31/555, A61K45/06, A61K47/542, A61K47/549

More from SOUTH DAKOTA BOARD OF REGENTS

Related pharmaceutical patents in our USPTO index.

  1. US 12428463

    Chimeric antigen receptors targeting abnormal glycobiology

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Expires Sep 25, 2045

    granted
  2. US 12427148

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  3. US 12428416

    ERK inhibitors and uses thereof

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  4. US 12427151

    Compositions and method of treating cancer

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  5. US 12427197

    Methods of producing cobalt nanoparticles and hollow metal nanospheres

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  6. US 12428489

    Human PD-L2 antibodies and methods of use therefor

    The Board of Regents of the University of Texas System · Expires Sep 25, 2045

    granted
  7. US 12427155

    Treatment for tau-related diseases

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  8. US 12428455

    Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells

    The Regents of the University of California · Expires Sep 25, 2045

    granted

Frequently asked questions

What is US patent 10383943?

US 10383943 (Compositions and related methods for the treatment of cancer) is held by SOUTH DAKOTA BOARD OF REGENTS. Status: granted. Granted Aug 20, 2019. Expires Aug 15, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10383943?

SOUTH DAKOTA BOARD OF REGENTS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.

When does US 10383943 expire?

Our index shows an expiration date of Aug 15, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.